Please assess the completion status of the following clinical trial:

Trial Title: Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presumptive diagnosis of smear-positive pulmonary TB within 2 weeks of study entry. Patients with both pulmonary and extrapulmonary disease are eligible.~* Documentation of HIV infection status. If HIV status is unknown at study entry, the participant must consent to testing and results must be available prior to study participation.~* Agree to use acceptable methods of contraception~Exclusion Criteria:~* History of adverse drug reaction to MOX, INH, RIF, PZA, or EMB~* Disease or condition for which MOX, INH, RIF, PZA, or EMB is contraindicated~* History of more than 14 days of continuous antituberculosis therapy during the previous 2 years or more than 2 months of antituberculosis therapy ever~* Active AIDS-related opportunistic infection or malignancy~* Currently receiving or planning to receive HIV protease inhibitors or nonnucleoside reverse transcriptase inhibitors in the first 2 months after study entry~* Silicotuberculosis~* Central nervous system TB~* Pregnant or breastfeeding~* Unable to take oral medication~* Electrocardiogram (EKG) QTc interval greater than 450 msec~* Taking classes IA or III antiarrhythmic agents (quinidine, procainamide, amiodarone, sotalol), cisapride, erythromycin, perphenazine/amitriptyline, phenothiazines, or tricyclic antidepressant~* Diseases or conditions for which treatment with other drugs with antituberculosis activity (e.g., rifabutin for MAC prophylaxis) is anticipated during the course of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks
- 2 (Type: PLACEBO_COMPARATOR): INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).